Vcanbio Cell & Gene Engineering Corp., Ltd

¥17.55As of Sun 8 Nov 2026, 12:00 UTC
SSE:600645Healthcare
Country China
PE (Fwd) •••
TSR 10Y CAGR (5.32%)
Div yield —
ROE 2.80%
Biotechnology
Beta (5Y) (0.01)
PE TTM 72.64
TSR TTM (28.83%)
Mkt cap ¥8.001B
ROIC 4.61%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥22
23.62%
(70.47%)
Hold 5|5|8|1|5
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.25
0.24
0.23
0.23
13.85%
10.70%
7.83%
(1.38%)
Revenue¥M
465.8
458.6
451.4
456.3
3.94%
3.46%
3.76%
2.94%
Peers (US$1.199B)
Cap (US$)
PE
1.189B
—
1.128B
50.13x
Capital
TTM
5Y
10Y
Leveragex
2.009
(0.296)
(0.244)
EBIT/Intx
0.718
0.431
0.400
Own earn%
(42.21)
10.61
14.64
Sh yield%
42.01
21.60
24.78
Owners
Insiders/Inst%
11.21
61.54
Short interest%
0.51
SBC / revenue%
5.33
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
3–8
$1 testx
0.1
Incr. ROIC%
13